Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Breast cancer-amplified sequence 3, a target of metastasis-associated protein 1, contributes to tamoxifen resistance in premenopausal patients with breast cancer

Gururaj, Anupama E ; Wigerup, Caroline LU ; Landberg, Göran LU and Kumar, Rakesh (2006) In Cell Cycle 5(13). p.1407-1410
Abstract
Lysine acetylation occurs in many protein targets, including core histones, transcription factors, and other proteins. Metastasis-associated protein 1 (MTA1) is implicated in the progression and metastasis of various epithelial tumors. Because MTA1 functions as a transcriptional coregulator, much of its role in cancer promoting processes are likely to involve its ability to regulate the transcription of downstream target genes that encode effector proteins. We recently showed that MTA1 could be post-translationally modified by acetylation, which modulates its function as a coregulator molecule. We also defined a chromatin target of MTA1, namely, breast cancer-amplified sequence 3 (BCAS3), in the context of which MTA1 behaves as a... (More)
Lysine acetylation occurs in many protein targets, including core histones, transcription factors, and other proteins. Metastasis-associated protein 1 (MTA1) is implicated in the progression and metastasis of various epithelial tumors. Because MTA1 functions as a transcriptional coregulator, much of its role in cancer promoting processes are likely to involve its ability to regulate the transcription of downstream target genes that encode effector proteins. We recently showed that MTA1 could be post-translationally modified by acetylation, which modulates its function as a coregulator molecule. We also defined a chromatin target of MTA1, namely, breast cancer-amplified sequence 3 (BCAS3), in the context of which MTA1 behaves as a transcriptional coactivator in breast cancer cells. Because the phenotypic effect of BCAS3 overexpression in tumors has not been defined, we investigated the consequence of increased expression of BCAS3 in human breast tumors. Here, we report that BCAS3 overexpression in hormone receptor-positive premenopausal breast cancer seemed to be associated with impaired responses to tamoxifen. Our findings have implications for endocrine therapy. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
endocrine, estrogen receptor, coactivator, acetylation, MTA1, BCAS3, resistance, breast cancer
in
Cell Cycle
volume
5
issue
13
pages
1407 - 1410
publisher
Landes Bioscience
external identifiers
  • wos:000239614600010
  • scopus:33746653428
ISSN
1551-4005
language
English
LU publication?
yes
id
3841199f-f7ba-47e7-9b40-cb7c1635df23 (old id 398492)
alternative location
http://www.landesbioscience.com/journals/cc/article/2924
date added to LUP
2016-04-01 11:47:24
date last changed
2022-01-26 18:18:56
@article{3841199f-f7ba-47e7-9b40-cb7c1635df23,
  abstract     = {{Lysine acetylation occurs in many protein targets, including core histones, transcription factors, and other proteins. Metastasis-associated protein 1 (MTA1) is implicated in the progression and metastasis of various epithelial tumors. Because MTA1 functions as a transcriptional coregulator, much of its role in cancer promoting processes are likely to involve its ability to regulate the transcription of downstream target genes that encode effector proteins. We recently showed that MTA1 could be post-translationally modified by acetylation, which modulates its function as a coregulator molecule. We also defined a chromatin target of MTA1, namely, breast cancer-amplified sequence 3 (BCAS3), in the context of which MTA1 behaves as a transcriptional coactivator in breast cancer cells. Because the phenotypic effect of BCAS3 overexpression in tumors has not been defined, we investigated the consequence of increased expression of BCAS3 in human breast tumors. Here, we report that BCAS3 overexpression in hormone receptor-positive premenopausal breast cancer seemed to be associated with impaired responses to tamoxifen. Our findings have implications for endocrine therapy.}},
  author       = {{Gururaj, Anupama E and Wigerup, Caroline and Landberg, Göran and Kumar, Rakesh}},
  issn         = {{1551-4005}},
  keywords     = {{endocrine; estrogen receptor; coactivator; acetylation; MTA1; BCAS3; resistance; breast cancer}},
  language     = {{eng}},
  number       = {{13}},
  pages        = {{1407--1410}},
  publisher    = {{Landes Bioscience}},
  series       = {{Cell Cycle}},
  title        = {{Breast cancer-amplified sequence 3, a target of metastasis-associated protein 1, contributes to tamoxifen resistance in premenopausal patients with breast cancer}},
  url          = {{http://www.landesbioscience.com/journals/cc/article/2924}},
  volume       = {{5}},
  year         = {{2006}},
}